NCT00251472View on ClinicalTrials.gov

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Paclitaxel Albumin Nanoparticle for Injectable Suspension

125mg/m2 by 30-minute IV infusion, once a week.

Trial Locations (1)

43215

Veeda Oncology, Columbus

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Veeda Oncology

OTHER